Alice Lee, MD
Appointments
Phone Appointments
myColumbiaDoctors
For existing patients, login to make an appointment, view documentation or contact your care provider.
Credentials & Experience
Board Certifications
- Pediatric Hematology-Oncology
- Pediatrics
Clinical Expertise
- Cancer Care
- Sarcoma
- Neuroblastoma
- Pediatric Solid Tumors
- Wilm's Tumor
Specialties
Education & Training
- Boston University School of Medicine
- Internship: St. John's Hospital, Springfield, IL
- Residency: St. John's Hospital, Springfield, IL
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
About Alice Lee
Alice Lee, MD specializes in the care of children and adolescents with solid tumors, especially neuroblastoma, Wilms' tumor, and sarcomas. She also conducts research to develop and evaluate new anticancer therapies for young patients.
Dr. Lee takes a personal interest in her patients. She says, "The patients I care for are amazing. Regardless of how a child is doing during treatment, they just want to be kids. I form bonds with their families that are rich and lifelong. They come to us each day hoping their children get better, while we come to work each day hoping to advance the field with more effective therapies so more children get better. My goal is to know I've done all we can for every one of our patients, and to further therapy by developing new anticancer drugs that become a standard part of care for pediatric cancers in the future."
Dr. Lee is also intrigued by the science of pediatric oncology. In this ever-changing field, much remains to be learned, which offers her an intellectual challenge. As the institution's principal investigator for the Children's Oncology Group (COG; the nation's leading pediatric cancer research consortium), Dr. Lee and her team are evaluating new therapies and new combinations of existing therapies to identify more effective, less toxic treatments for children with cancer.
Dr. Lee is proud to be part of the team at NewYork-Presbyterian/Morgan Stanley Children's Hospital at Columbia University Medical Center, where patients have all the specialists they may need in one location, including pediatric critical care onsite if serious complications arise. Her division has leaders in every type of pediatric cancer or blood disorder.
Academic Titles
- Assistant Professor of Pediatrics at CUMC
Administrative Positions
- Medical Director
Hospital Affiliations
- NewYork-Presbyterian/Morgan Stanley Children's Hospital
- NewYork-Presbyterian/Columbia
Gender
- Female
Insurance Accepted
Aetna
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Signature Administrators
- Student Health
Affinity
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Amida Care
- Special Needs Plan
Cigna
- EPO
- Great West
- HMO
- POS
- PPO
Emblem/GHI
- HMO
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield
- Blue Priority
- EPO
- HMO
- Medicare (Mediblue)
- NYP Employee Plan
- Pathway (Exchange)
- POS
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare
- MagnaCare
Medicare
- Traditional Medicare (NY)
Multiplan
- Multiplan
Oxford Health Plans
- Freedom
- Liberty
- Medicare Managed Care
UnitedHealthcare
- Columbia University Employee Plan
- Compass (Exchange)
- EPO
- Essential Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
WellCare
- Medicaid Managed Care
- Medicare Managed Care
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Contact & Locations
New York, New York 10032
Research
Clinical Trials
NCT01371981 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
NCT01595048 Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - This study is ongoing, but not recruiting participants.
NCT02101853 Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
NCT02166463 A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
NCT02723994 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Grants
A PHASE 1/2 STUDY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS (P&S Industry Clinical Trial)
Nov 12 2018 - Nov 12 2023
A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, PHASE I/II STUDY OF PI3K INHIBITOR COPANLISIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY SOLID TUMORS OR LYMPHOMA SAFETY, TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF COPANLISIB IN PEDIATRIC PATIENTS (P&S Industry Clinical Trial)
Oct 22 2018 - Oct 22 2023
SERVICE AGREEMENT - GLADE-BENDER E7080-A-001-216/ADVL1711 (P&S Industry Clinical Trial)
Apr 5 2018 - Apr 5 2023
A PHASE 1 STUDY OF PEVONEDISTAT (MLN4924, IND# 136078), A NEDD8 ACTIVATING ENZYME (NAE) INHIBITOR, IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)
Mar 28 2018 - Mar 28 2023
A PHASE II STUDY OF PAZOPANIB (GW786034, NSC# 737754) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)
Dec 15 2017 - Dec 15 2022
A PHASE 1 STUDY OF LY2606368, A CHK1/2 INHIBITOR, IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS (P&S Industry Clinical Trial)
Jun 12 2017 - Jun 12 2022
A MULTICENTER, RANDOMIZED, PHASE 2 STUDY TO ASSESS THE FEASIBILITY, SAFETY AND EFFICACY OF OTO-104 GIVEN BY INTRATYMPANIC ADMINISTRATION IN SUBJECTS AT RISK FOR OTOTOXICITY FROM CISPLATIN CHEMOTHERAPY REGIMENS IN THE TREATMENT OF CANCER (P&S Industry Clinical Trial)
Feb 15 2017 - Feb 17 2022
A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (P&S Industry Clinical Trial)
Jul 14 2016 - Jul 14 2021
A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN HILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS (P&S Industry Clinical Trial)
Mar 22 2016 - Mar 22 2021
A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB (P&S Industry Clinical Trial)
Jul 16 2015 - Jul 16 2020
PHASE 1B/2 STUDY OF CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE, MITOXANTRONE, PEG-ASPARAGINASE, AND VINCRISTINE (UK R3 INDUCTION BACKBONE) IN CHILDREN WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (P&S Industry Clinical Trial)
Apr 15 2015 - Apr 15 2020
A MULTI-CENTER, OPEN LABEL, NON-CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN CHRONIC PHASE (CP) OR WITH PH+ CML IN CP OR ACCEL (P&S Industry Clinical Trial)
Aug 18 2014 - Aug 31 2019
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2019
STUDY CHAIR-NIH NATIONAL CLINICAL TRIALS NETWORK (NCTN) PCR (Federal Gov)
Mar 1 2017 - Feb 28 2019
NIH NATIONAL CLINICAL TRIALS NETWORK (NCTN) PCR (Federal Gov)
Mar 1 2014 - Feb 28 2019
ADVL0921, A PHASE II STUDY OF MLN8237 (IND# 102984), A SELECTIVE AURORA A KINASE INHIBITOR IN CHILDREN WITH RECURRENT/REFRACTORY SOLID TUMORS AND LEUKEMIAS. (P&S Industry Clinical Trial)
Dec 18 2013 - Dec 31 2018
PER CASE REIMBURSEMENT AND PATIENT STUDIES (Federal Gov)
Aug 1 2014 - Sep 30 2018
SUPPORT, NIH COG PHASE 1 GRANT (Federal Gov)
Aug 1 2014 - Sep 30 2018
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2018
DIV-NB-201 (NCI:9347) - IRB: AAAK7751 (P&S Industry Clinical Trial)
Jan 23 2013 - Jan 23 2018
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2017
EVERYCHILD (APEC14B1) (Private)
Oct 26 2015 - Feb 28 2017
CANCER TRIALS SUPPORT UNIT (CTSU) PHASE II SUPPLEMENTAL PAYMENTS (N02-CM-62212) (Federal Gov)
Jan 4 2015 - Jan 3 2017
PER CASE REIMBURSEMENT AND PATIENT STUDIES (Federal Gov)
Aug 1 2014 - Jul 31 2016
SUPPORT, NIH COG PHASE 1 GRANT (Federal Gov)
Aug 1 2014 - Jul 31 2016
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2016
SUNCOAST CCOP RESEARCH BASE AT THE UNIVERSITY OF SOUTH FLORIDA (Federal Gov)
Jan 1 2016 - May 31 2016
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2015
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2014
PEDIATRIC CANCER FOUNDATION DEVELOPMENTAL THERAPEUTICS PROGRAM (PCFDTP) (Private)
Jul 1 2005 - Jun 30 2013
PEDIATRIC CANCER RESEARCH FOUNDATION (Private)
Jul 1 2005 - Jun 30 2013
MASTER SUBAWARD AGREEMENT FOR NON-INDUSTRY FUNDING SOURCES (Private)
Apr 26 2012 - Apr 25 2013
COG MASTER FOR NON-INDUSTRY STUDIES (Federal Gov)
Mar 1 2012 - Feb 28 2013
COG ARRA (Federal Gov)
Jun 1 2009 - May 31 2012
NATIONAL CHILDHOOD CANCER FOUNDATION-CHILDREN S ONCOLOGY GROUP COMMUNITY CLINICAL PROGRAM GRANT (Federal Gov)
Jun 1 2004 - May 31 2012
CHILDREN S ONCOLOGY GROUP CHAIR S GRANT (Federal Gov)
Mar 1 2008 - Feb 29 2012
CHILDREN''S ONCOLOGY GROUP CHAIR''S GRANT (Federal Gov)
Mar 1 2008 - Feb 29 2012
For a complete list of publications, please visit PubMed.gov